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To evaluate CV risk in the saxagliptin phase 2b/3 clinical trials, two major composite end points were defined:
● Acute CV Events comprised ischaemic events that were acute and consequential, including both reversible and 
irreversible ischaemic events, as well as revascularisation procedures.
● Major Adverse Cardiovascular Events (MACE) encompassed CV death, nonfatal myocardial infarction, and nonfatal 
stroke.
● Acute CV Events and MACE were identified in the adverse event database of phase 2b/3 studies by searching for 
events that coded to particular terms in the Medical Dictionary for Regulatory Activities (MedDRA) using the methods 
described in Figure 1. For MACE, case identification was supplemented by clinical review of all deaths to ensure that 
each death with a CV aaetiology was counted.
A meta-analysis of Acute CV Events and MACE was performed by pooling data from randomised, controlled phase 2b/3 studies 
of saxagliptin in type 2 diabetes (T2D). Analytic methods are described below and the set of clinical studies included in the 
meta-analysis is described in Figure 2. The meta-analysis included patients exposed to doses of 2.5 – 100 mg of saxagliptin
once daily; the proposed usual clinical dose is 5 mg once daily.
Diabetes is Australia’s fastest growing chronic disease with approximately 890,000 patients currently diagnosed with diabetes.1
By 2031 it is predicted that 3.3 million Australians will have type 2 diabetes mellitus,2 thus increasing the demand for treatment. 
However, several diabetes, obesity, and lipid drug trials have had unexpected and unfavourable cardiovascular (CV) results. The 
saxagliptin (SAXA) phase 2b/3 program enrolled a range of patients with diabetes and included a controlled, long-term safety 
extension phase. SAXA is a potent, selective dipeptidyl peptidase-4 (DPP-4) inhibitor. In the SAXA clinical data, the primary 
endpoint, major adverse cardiovascular events (MACE; stroke, myocardial infarction or CV death, analysed post hoc) and acute 
cardiovascular events (ACE; acute, clinically significant events, including cardiac revascularisation procedures) were identified 
using selected MedDRA Preferred Terms. CV events were analysed in a comprehensive dataset: 8 randomised, double-blind, 
phase 2b/3 trials, which included 4607 patients (3206 randomised to SAXA 2.5, 5, or 10 mg; 150 randomised to SAXA 20, 40, or 
100 mg; and 1251 randomised to placebo, metformin, or up-titrated glyburide). Overall exposure was 3758 patient-years on 
SAXA and 1293 patient-years on comparators. Within the SAXA population, 81% had at least 1 CV risk factor in addition to 
diabetes, with hypertension (52%), dyslipidaemia (44%), or history of smoking (39%) the most common; 12% had known prior 
CV disease. Comparator group had similar proportions. Numbers of patients with events are shown in Table. The Cox 
proportional hazard ratio for MACE was 0.44 (95% CI: 0.24–0.82) and for ACE was 0.59 (95% CI: 0.35–1.00). A series of 
sensitivity analyses using related endpoints and alternative analytic methods produced consistent results. Based on a >5000 
patient-year clinical trial experience, there was no evidence of increased CV risk with SAXA treatment ― as monotherapy or in 
combination with other oral antidiabetic agents. These data raise the hypothesis of a cardioprotective effect of SAXA, which will 
be studied in the SAVOR trial.
There has been considerable scrutiny of the CV safety of some antidiabetic agents, including sulfonylureas and PPAR gamma 
agonists. Concerns regarding the safety of antidiabetic agents are based on data from randomised clinical trials and 
observational studies.
Based on data available prior to initiating the phase 2b/3 studies, there was no a priori concern that increased CV risk would be 
associated with saxagliptin. These data include:
● No microscopic evidence of cardiotoxicity in any nonclinical species.
● No indication of adverse CV effects based on in vitro (hERG, Purkinje) or 
in vivo (ECG, haemodynamic) assessments in rat, dog, or monkey.
● No adverse effect on lipid parameters, blood pressure, heart rate, or QTc in phase 1 studies.
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Figure 1. Process for Identifying Acute CV Events and MACE
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● Summary of baseline characteristics:
– Demographic, diabetes, CV risk, CV history
● Frequency of patients with events overall and by treatment group
● Incidence rates (adjusted for exposure) for combined saxagliptin groups overall, and within specified subgroups
● Assessment of risk ratios from controlled phase 2b/3 data (stratified by study):
– Incidence Rate Ratio (adjusted for exposure)
• Mantel-Haenszel (MH)
• Exact method
– Cox Proportional Hazards Model
– Incidence Ratio (MH, not adjusted for exposure)
● Assessment of risk ratios overall, and in individual studies:
– Individual: Incidence Rate Ratio with Bayesian credibility interval
– Overall: Incidence Rate Ratio (MH)
● Time to first event by weighted Kaplan-Meier estimate:
– Weights proportional to overall study sample size
ANALYTIC METHODS
There was no evidence of increased risk of CV events:
● in the phase 2b/3 pooled population 
● in subgroups of patients expected to be at higher risk 
● in individual studies
Data presentations:
● Demographic and Baseline Characteristics (Table 1)
● CV Risk Factors (Table 2)
● Frequency of CV End Points (Table 3)
● Incidence Rate for MACE in Subgroups Expected to Be at Higher Risk (Figure 3)
● Incidence Rate Ratio of MACE in the Pooled Population and by Study (Figure 4)
● Stratified Analyses of MACE and Acute CV Events (Figure 5)
● Time to Onset of First MACE (Figure 6)
● Time to Onset of Death (Figure 7)
RESULTS
Controlled Phase 2b/3 Pooled Population
Table 2. CV Risk Factors (in Addition to T2D) 
165 (13)404 (12)118 (12)150 (12)118 (13)Patients With History of CV Diseaseb
Number (%) of Patients  
SAXA
2.5 mg
n=937
SAXA
5 mg
n=1269
SAXA
10 mg
n=1000
All SAXAc
n=3356
Control
n=1251
Patients With at Least 
One CV Risk Factor 
in Addition to T2D
777 (83) 1015 (80) 803 (80) 2724 (81) 1035 (83)
Hypertension 519 (55) 655 (52) 510 (51) 1750 (52) 688 (55)
Hypercholesterolaemiaa 471 (50) 565 (45) 353 (35) 1475 (44) 566 (45)
Smoking History 383 (41) 449 (35) 393 (39) 1301 (39) 471 (38)
First-degree Family 
Member With
Premature Coronary
Heart Disease
190 (20) 248 (20) 186 (19) 677 (20) 265 (21)
a Includes mixed dyslipidaemia.
b Prior CV disease defined as previous myocardial infarction, congestive heart failure, hospitalisation for unstable angina, stable angina, 
percutaneous coronary intervention, coronary artery bypass graft, coronary artery disease, cerebrovascular disease, peripheral vascular 
disease.
c Includes 20, 40, and 100 mg experience from Study 008.
Mean (SD) %
Mean (SD) yrs
Mean
Female, n (%)
Male, n (%)
Other
Asian
Black
White
Non-white, n 
(%)
White, n (%)
Mean (SD) yrs
Body Mass Index (kg/m2)
Table 1. Demographic and Baseline Characteristics
8.4 (1.23)8.5 (1.26)9.0 (1.42)8.5 (1.18)8.1 (0.99)HbA1c
SAXA 
2.5 mg
n=937
SAXA
5 mg
n=1269
SAXA
10 mg
n=1000
All SAXAa
n=3356
Controlb
n=1251
Age 54.6 (10.0) 53.7 (10.3) 52.7 (10.7) 53.6 (10.3) 53.9 (10.6)
Race 650 (69)                902 (71) 775 (78)       2456 (73) 889 (71)
287 (31) 367 (29) 225 (23) 900 (27) 362 (29)
Race, n (%)
650 (69.4) 902 (71.1) 775 (77.5) 2456 (73.2) 889 (71.1)
36 (3.8) 62 (4.9) 38 (3.8) 149 (4.4) 50 (4.0)
155 (16.5) 206 (16.2) 125 (12.5) 493 (14.7) 195 (15.6)
96 (10.2) 99 (7.8) 62 (6.2) 258 (7.7) 117 (9.4)
Gender 444 (47)        625 (49)        495 (50)       1659 (49) 620 (50)
493 (53)        644 (51)        505 (51)       1697 (51) 631 (50)
30.4 30.3 30.6 30.4 30.3
Duration of T2D
5.1 (5.2) 4.1 (5.1) 2.5 (3.6) 3.8 (4.8) 4.1 (5.0)
a Includes 20, 40, and 100 mg experience from Study 008.
b Includes metformin monotherapy from Study 039.
Number (%) With Event
Table 3. Frequency of CV End Points
10 (0.8)7 (0.2)4 (0.4)2 (0.2)1 (0.1)CV Death
SAXA 2.5 mg SAXA 5 mg SAXA 10 mg All SAXAa Control
N (Total Patients) 937 1269 1000 3356 1251
Total Patient-Years 1149 1462 1119 3758 1293
Mean Duration of
Follow-up (yrs) 1.23 1.15 1.12 1.12 1.03
MACE 6 (0.6) 6 (0.5) 11 (1.1) 23 (0.7) 18 (1.4)
Acute CV Events 14 (1.5) 10 (0.8) 14 (1.4) 38 (1.1) 23 (1.8)
All Death 3 (0.3) 3 (0.2) 4 (0.4) 10 (0.3) 12 (1.0)
a Includes 20, 40, and 100 mg experience from Study 008.
Figure 3. Incidence Rate for MACE in Subgroups Expected to Be at Higher Risk
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Figure 4. Incidence Rate Ratio of MACE in the Pooled Population and by Study
Figure 5. Stratified Analyses of MACE and Acute CV Events
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aExact method.
bMantel-Haenszel method.
Data represent point estimate and 95% CI.
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Data represent point estimate and 95% CI.
Size of point estimate is relative to number of events.
Pooled phase 2b/3 CI based on MH.
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Figure 6. Time to Onset of First MACE
Figure 7. Time to Onset of Death
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Figure 2. Controlled Phase 2b/3 Clinical Studies Pooled to Assess CV Safety
MET=metformin; OL=open-label; SU=sulfonylurea; TZD=thiazolidinedione.
Dataset:
● Short-term plus long-term experience
● 5051 patient-years of exposure
● 3758 patient-years of exposure to saxagliptin
All Patients  N=4607
Phase 3
N=4184
Mechanism of Action 
Study 041
N=36
Monotherapy
N=766
Add-on
Combination
N=2076
Study 011
N=401
Study 038
N=365
Add-on to MET
Study 014
N=743
Add-on to SU
Study 040
N=768
Add-on to TZD
Study 013
N=565
Initial Comb. With MET 
Study 039
N=1306
Phase 2b
Study 008
N=423 ● Analysed multiple CV end points using multiple analytic techniques to assess consistency of results.
● Analysed CV end points in phase 2b/3 pooled population by subgroup and by study.
● No evidence of increased CV risk in patients with T2D exposed to saxagliptinfor up to 2.5 years.
● Data raise hypothesis of a cardioprotective effect of saxagliptin, which merits further study.
CARDIOVASCULAR SAFETY 
SUMMARY AND CONCLUSIONS
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